16 October 2018 - - US-based clinical-stage biotechnology company Allogene Therapeutics, Inc. (NASDAQ: ALLO) has closed its initial public offering of 20.7m shares of its common stock, at a price to the public of USD 18.00 per share the company said.

The total includes 2.7m shares sold pursuant to the exercise in full by the underwriters of their option to purchase additional shares.

Including the option exercise, the gross proceeds to Allogene Therapeutics from the offering, before deducting the underwriting discounts and commissions and offering expenses, were USD 372.6m.

Goldman Sachs and Co. LLC, J.P. Morgan Securities LLC, Cowen and company, LLC and Jefferies LLC acted as the joint book-running managers for the offering.

Allogene Therapeutics, with headquarters in South San Francisco, is a clinical stage biotechnology company pioneering the development of allogeneic chimeric antigen receptor T-cell (AlloCAR T) therapies for cancer.